Maynard Um
-
-
-
-
-
-
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
-
-
-
-
-
-
BioCryst reports 2025 ORLADEYO revenue of $601 million, up 37%
-
-
-
-
-
-
-
BioCryst presents pediatric HAE data at medical conference
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) PT Raised to $27 at Citizens on Navenibart Deal, Strong HAE Fit
-
-
-
-
-
-
-
BioCryst chief research officer to depart September 1
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Achieves Reimbursement for ORLADEYO Across all Major European Countries
-
-
-
-
-
-
-
Cantor Fitzgerald Starts BioCryst Pharma (BCRX) at Overweight
-
401,681 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

